2013 Fiscal Year Final Research Report
Development of novel molecular targeted therapies for the treatment of KRas mutated non small lung cancer using a HSP90 inhibitor
Project/Area Number |
23592078
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Thoracic surgery
|
Research Institution | Kawasaki Medical School |
Principal Investigator |
MORITA ICHIRO 川崎医科大学, 医学部, 准教授 (30200413)
|
Project Period (FY) |
2011 – 2013
|
Keywords | KRas / HSP90 / inhibitor |
Research Abstract |
Hsp90 inhibitors are substances that inhibit the activity of the Hsp90 heat shock protein. Since Hsp90 stabilizes a variety of proteins required for survival of cancer cells, these substances may have therapeutic benefit in the treatment of various types of malignancies. In the present study, we have evaluated the antitumor effects of a novel HSP90 inhibitor, AUY922 for the treatment of lung cancer. AUY922 suppressed cell viability and induced apoptosis in KRas addicted pulmonary adenocarcinoma cells. More, the inhibitor showed antitumor effect in EGFR-TK mutation or EML4-ALK positive lung cancer cells. These results indicate that AUY922 looks to be a promising treatment for non small cell lung cancer including pulmonary adenocarcinoma harboring KRas mutation.
|
-
-
[Presentation] K-ras及びMycを標的とした新規非小細胞肺癌治療法の開発2011
Author(s)
深澤拓也,森田一郎,木下真一郎,吉田和弘,山辻知樹,繁光薫,林次郎,松岡順次,前田豊, Durbin Mary, Soucek Laura,猶本良夫
Organizer
第52回日本肺癌学会総会
Place of Presentation
大阪府大阪市
Year and Date
2011-11-04
-